Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405577 | 1.00 | ALDH1A1 (0.55) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL7066161 | 0.93 | ALDH1A1 (0.66) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL7070251 | 0.93 | ALDH1A1 (0.66) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL6375413 | 0.85 | ITGA4 (0.62) | ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL7070244 | 0.84 | ALDH1A1 (0.54) | ALDH1A1ITGB1ITGA4ITGB7MEN1 | |
| SCHEMBL2879402 | 0.81 | ITGB1 (0.77) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL2879404 | 0.81 | ITGB1 (0.77) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL27877728 | 0.81 | ITGB1 (0.77) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL2879401 | 0.81 | ITGB1 (0.77) | ALDH1A1ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL5204476 | 0.78 | ITGA4 (0.68) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 369/4885ITGB1 35/4885ITGA5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.